Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

HISTOSELECT: How to Overcome Challenges in Antibody Selection?

HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).

COVID-19 Testing at Cerba Research